

were significantly altered. **DISCUSSION/SIGNIFICANCE OF IMPACT:** Our results reveal novel genetic targets that underlie plasticity of fear-memory circuitry via their contribution of NMDAR-mediated fear consolidation and can inform future strategies for targeting fear related disorders like PTSD. **CONFLICT OF INTEREST DESCRIPTION:** Anantha Shekhar and Yvonne Lai are co-founders of Anagin, Inc., which is developing some of the related molecules for the treatment of PTSD.

4528

Sirtuin 3 activation as a potential renoprotective therapy in a mouse model of Alport syndrome

Bryce Jones¹, Komuraiah Myakala², Xiaoxin Wang², Andrew Libby², Shogo Takahashi², Kanchan Bhasin², Suman Ranjit², Avi Rosenberg³, and Moshe Levi²

¹Georgetown - Howard Universities; ²Georgetown University;

³Johns Hopkins University

OBJECTIVES/GOALS: Sirtuin 3 (Sirt3), a mitochondrial NAD⁺-dependent deacetylase, is decreased in diverse models of kidney disease, and Sirt3 activation prevents disease progression in many of those models. We are investigating if pharmacological activation of Sirt3 ameliorates kidney disease in a mouse model of Alport syndrome. **METHODS/STUDY POPULATION:** Alport syndrome is a hereditary orphan disease arising from a defect in the collagen IV $\alpha3\alpha4\alpha5$ heterotrimer, a component of the glomerular basement membrane. Male and female Col4a3^{tm1Dec} knockout mice and wild type controls on the 129X1/SvJ background were harvested at 9–10 weeks of age. Serum and urine were collected prior to euthanasia; renal pathology was assessed by histology; and renal cortical mRNA and protein levels were assessed by qRT-PCR and western blot, respectively. Studies are ongoing using dietary administration of a Sirt3 activator, nicotinamide riboside (500 mg/kg/day), in Col4a3 transgenic mice on both the 129X1/SvJ and C57BL/6J backgrounds. **RESULTS/ANTICIPATED RESULTS:** Col4a3^{-/-} mice have elevated BUN (P < 0.0001, both sexes), serum creatinine (P < 0.001, male; P < 0.0001, female), and urinary albumin-to-creatinine ratio (P < 0.0001, both sexes) compared to Col4a3^{+/+} controls. On histology, Col4a3^{-/-} mice have extensive renal fibrosis compared to Col4a3^{+/+} controls. Sirt3 expression is decreased in the renal cortices of Col4a3^{-/-} mice at the mRNA (P < 0.0001, male; trend, P = 0.07, female) and protein levels (P < 0.05, male; P < 0.001, female) compared to Col4a3^{+/+} controls. All experiments had 5–9 mice per group. Results of the prevention study with nicotinamide riboside, a Sirt3 activator, are unknown at the time of abstract submission. **DISCUSSION/SIGNIFICANCE OF IMPACT:** Col4a3^{-/-} mice have severe renal impairment and decreased renal cortical expression of Sirt3 at the mRNA and protein levels compared to Col4a3^{+/+} controls. However, it is unknown at this time if pharmacologically activating Sirt3 prevents this renal decline.

4094

Structural Determinants of Immunogenicity for Peptide-Based Immunotherapy

Jason Devlin, University of Notre Dame¹, Jesus Alonso², Grant Keller², Sara Bobisse³, Alexandre Harari³, and Brian Baker²

¹Indiana University School of Medicine; ²University of Notre Dame;

³UNIL CHUV, Ludwig Institute for Cancer Research, Switzerland

OBJECTIVES/GOALS: Neoantigen vaccine immunotherapies have shown promise in clinical trials, but identifying which peptides to

include in a vaccine remains a challenge. We aim to establish that molecular structural features can help predict which neoantigens to target to achieve tumor regression. **METHODS/STUDY POPULATION:** Proteins were prepared by recombinant expression in *E. coli* followed by *in vitro* refolding. Correctly folded proteins were purified by chromatography. Affinities of protein-protein interactions were measured by surface plasmon resonance (SPR) and thermal stabilities of proteins were determined by differential scanning fluorimetry. All experiments were performed at least in triplicate. Protein crystals were obtained by hanging drop vapor diffusion. The protein crystal structures were solved by molecular replacement and underwent several rounds of automated refinement. Molecular dynamics simulations were performed using the AMBER molecular dynamics package. **RESULTS/ANTICIPATED RESULTS:** A T cell receptor (TCR) expressed by tumor-infiltrating T cells exhibited a 20-fold stronger binding affinity to the neoantigen peptide compared to the self-peptide. X-ray crystal structures of the peptides with the major histocompatibility complex (MHC) protein demonstrated that a non-mutated residue in the peptide samples different positions with the mutation. The difference in conformations of the non-mutated residue was supported by molecular dynamics simulations. Crystal structures of the TCR engaging both peptide/MHCs suggested that the conformation favored by the mutant peptide was crucial for TCR binding. The TCR bound the neoantigen/MHC with faster binding kinetics. **DISCUSSION/SIGNIFICANCE OF IMPACT:** Our results suggest that the mutation impacts the conformation of another residue in the peptide, and this alteration allows for more favorable T cell receptor binding to the neoantigen. This highlights the potential of non-mutated residues in contributing to neoantigen recognition.

4322

Structure-guided design of the TIL1383I T cell receptor

Jesus Alonso¹, Nishant Singh, Jason Devlin¹, Lauren Davancaze, and Brian Baker

¹University of Notre Dame

OBJECTIVES/GOALS: Our goal is to employ a structure-guided design approach to engineering a safer and more effective variant of the TIL1383I T cell receptor (TCR) currently under study in clinical trials for malignant melanoma. **METHODS/STUDY POPULATION:** Using our unpublished structure of TIL1383I we are in process of designing a panel of TCR variants with the goal of identifying candidates that improve “focus” towards the tyrosinase antigen presented on the MHC class I molecule HLA-A2. **RESULTS/ANTICIPATED RESULTS:** Structural analysis of TIL1383I revealed key residues, particularly beta-chain residues E97, G101, L102, responsible for engaging the tyrosinase peptide bound to HLA-A2. The crystal structure of TIL1383I in complex with tyrosinase-HLA-A2 also highlighted its uncharacteristic binding geometry and we therefore hypothesize that this binding orientation is associated with the observed CD8 co-receptor independence of TIL1383I. Indeed, functional analysis with TIL1383I-transduced CD8-positive and CD8-negative T cells, transduced T cells expressing a truncated CD8 lacking the intracellular LCK signaling domain, and tyrosinase peptide variants presented by HLA-A2 mutants outline this co-receptor independence. Combined with our interrogation of tyrosinase peptide cross-reactivity via a peptide positional scanning library approach, structure-guided design resulted in the identification of TIL1383I variants with improved binding affinities to the tyrosinase